ArticleBMC complementary medicine and therapies2025
Differential oxido-reductive activities of aged garlic extract and S-allyl-cysteine in genetically modified Drosophila model of Alzheimer's disease.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings.Natural products and bioprospecting · 2026Review
- Organ-Dependent Antioxidant, Redox-Modulating, and Lifespan Effects ofFood science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder frequently associated with ageing. It is characterised by the loss of neurons in the hippocampus and cortex, leading to declines in cognitive function and memory. Recent research has spotlighted Aged Garlic Extract (AGE) and its bioactive component, S-allyl-cysteine (SAC), as promising candidates for the treatment of AD due to their potent antioxidant, anti-inflammatory, and neuroprotective properties. These features help mitigate oxidative stress and neuronal damage associated with the disease. The present study aimed to evaluate the neuroprotective effects of AGE and SAC using a Drosophila melanogaster (Drosophila) model of Alzheimer’s disease. The Drosophila (UAS-Aβ > Elav-GAL4) were reared on a diet supplemented with varying concentrations of AGE (10 µL, 20 µL, and 40 µL) and SAC (at doses of 25, 50, and 75 mg/kg). Key parameters measured included larval motility, negative geotaxis, and oxidative stress markers. The AD models exhibited reduced motor abilities, decreased antioxidant levels, increased oxidative stress, and elevated acetylcholinesterase (AChE) activity. However, treatment with different concentrations of AGE and SAC significantly improved locomotor function and modulated redox activities, along with a reduction in AChE activity. This study highlights the neuroprotective potential of AGE and its active component, SAC, in the Drosophila AD model, indicating that the beneficial effects of AGE are primarily attributed to SAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.